首页> 外文期刊>Onkologie >A case of positive mixed epithelial/mesenchymal metaplastic breast Carcinoma (Carcinosarcoma). towards novel therapeutic targets: Case report
【24h】

A case of positive mixed epithelial/mesenchymal metaplastic breast Carcinoma (Carcinosarcoma). towards novel therapeutic targets: Case report

机译:上皮/间质化生混合乳癌(癌肉瘤)阳性的病例。寻求新的治疗目标:病例报告

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Metaplastic breast cancer (MeBC) is a rare malignancy, representing less than 1% of all breast cancers. We present a case of triple-negative MeBC with a biphasic growth pattern, including malignant mesenchymal and epithelial components. Case Report: A 45-year-old female patient presented to our hospital with a 1-month history of a lump in her right breast. Upon clinical examination, a mass measuring 24 mm in diameter was revealed at 10-11 o'clock in the outer upper quadrant of the right breast. The patient was submitted for ultrasound scanning, ultrasound-guided core needle biopsy, and excisional biopsy which revealed a mixed epithelial/mesenchymal tumor, 8 cm in diameter. A complete immunohistochemical profile was presented. A right modified radical mastectomy with axillary lymph node dissection was performed and was tolerated well by the patient. The histological diagnosis of the lesion was MeBC with the epithelial component consistent with a grade 3 ductal adenocarcinoma. The 14 dissected axillary nodes were not involved. The patient was later submitted for adjuvant chemotherapy and radiotherapy. To date, 24 months postoperatively, the patient remains without any signs or symptoms of residual disease or recurrence. Conclusion: The aggressive behavior and chemoresistance of MeBC warrants early diagnosis and treatment to achieve optimal outcome.
机译:背景:化生性乳腺癌(MeBC)是一种罕见的恶性肿瘤,仅占所有乳腺癌的不到1%。我们提出了一例三阴性MeBC,具有双相生长模式,包括恶性间质和上皮成分。病例报告:一名45岁的女性患者到我院就诊,其右乳房有一个肿块1个月的病史。经过临床检查,在右乳房的上象限的10-11点处发现了直径为24毫米的肿块。该患者接受了超声扫描,超声引导的芯针活检和切除活检,这些活检显示了直径为8 cm的混合上皮/间质肿瘤。提出了完整的免疫组化图谱。进行了右侧腋窝淋巴结清扫术并接受了患者的良好耐受。病变的组织学诊断为MeBC,其上皮成分与3级导管腺癌一致。解剖的14个腋窝结节均未参与。该患者随后接受辅助化疗和放疗。迄今为止,术后24个月,患者仍然没有残留疾病或复发的任何体征或症状。结论:MeBC的攻击行为和化学耐药性值得早期诊断和治疗以达到最佳效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号